---
schema_version: "secwatch.filing_event.v1"
accession: "0001736730-25-000068"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:18:49.928378+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CAMP4 reports Q2 net loss of $12.6M; cash $39.1M; pipeline advances in SYNGAP1 and UCD programs

## Summary
- Net loss of $12.6M for Q2 2025, flat vs Q2 2024; R&D expenses $10.3M, G&A $4.2M.
- Cash, cash equivalents and marketable securities $39.1M as of June 30, 2025, down from $49.3M on March 31, 2025.
- SYNGAP1 program: translational data presented at ASGCT; GLP tox studies start Q3 2025; potential Phase 1/2 trial in H2 2026.
- CMP-CPS-001 (UCD): completed dosing in MAD cohort 3; safety and biomarker data from SAD and MAD cohorts expected Q4 2025.

## SEC filing metadata
- accession: 0001736730-25-000068
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000068/0001736730-25-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000068/camp-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001736730-25-000068
- JSON: https://secwatch.observer/filing/0001736730-25-000068.json
- Plain text: https://secwatch.observer/filing/0001736730-25-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.